Holger N. Lode
Impact in
- Neurology top 0.5%
- Neuroblastoma Research and Treatments
- Immunology top 2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Neurology 103
- Neuroblastoma Research and Treatments 100
- Immunology 47
- Immunotherapy and Immune Responses 29
- Co-authors
- Ralph A. Reisfeld (25 shared papers)Stephen D. Gillies (19 shared papers)Rong Xiang (15 shared papers)Nissi M. Varki (6 shared papers)Doron Shabat (6 shared papers)Gerhard Gaedicke (26 shared papers)Nikolai Siebert (36 shared papers)Carrie S. Dolman (8 shared papers)
- Journals
- Cancers (13 papers)Proceedings of the National Academy of Sciences (6 papers)Cancer Letters (6 papers)Blood (6 papers)OncoImmunology (5 papers)
- Partner nations
- GermanyUnited StatesAustria
In The Last Decade
Holger N. Lode
187 papers receiving 5.8k citations
Holger N. Lode's Hit Papers
Peers
Comparison fields: 5 of 134
- Neurology 2.2k
- Immunology 1.8k
- Oncology 1.9k
- Cancer Research 680
- Biotechnology 312
Countries citing papers authored by Holger N. Lode
This map shows the geographic impact of Holger N. Lode's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holger N. Lode with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holger N. Lode more than expected).
Fields of papers citing papers by Holger N. Lode
This network shows the impact of papers produced by Holger N. Lode. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holger N. Lode. The network helps show where Holger N. Lode may publish in the future.
Co-authors
The 25 scholars most cited alongside Holger N. Lode, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 201 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial Hit paper breakdown → | 2018 | 307 |
| 2 | 2015 | 247 | |
| 3 | 2012 | 206 | |
| 4 | 2004 | 191 | |
| 5 | 2011 | 177 | |
| 6 | 1998 | 168 | |
| 7 | 1997 | 155 | |
| 8 | 2000 | 140 | |
| 9 | 2020 | 120 | |
| 10 | 1999 | 116 | |
| 11 | 2001 | 101 | |
| 12 | 2019 | 99 | |
| 13 | 2005 | 98 | |
| 14 | 2001 | 88 | |
| 15 | 1998 | 83 | |
| 16 | Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. | 1997 | 82 |
| 17 | 2001 | 82 | |
| 18 | 2004 | 82 | |
| 19 | 2008 | 82 | |
| 20 | 2014 | 78 |
About Holger N. Lode
Holger N. Lode is a scholar working on Neurology, Immunology, Oncology, Molecular Biology and Cancer Research, having authored 201 papers that have together received 6.0k indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (100 papers), Immunotherapy and Immune Responses (29 papers), Cancer therapeutics and mechanisms (21 papers), CAR-T cell therapy research (20 papers), Virus-based gene therapy research (18 papers), Cancer, Hypoxia, and Metabolism (15 papers), Lung Cancer Research Studies (13 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). The work is most often cited by research in Neurology (2.2k citations), Immunology (1.8k citations), Oncology (1.9k citations), Cancer Research (680 citations) and Biotechnology (312 citations). Holger N. Lode has collaborated with scholars based in Germany, United States and Austria. Frequent co-authors include Ralph A. Reisfeld, Stephen D. Gillies, Rong Xiang, Nissi M. Varki, Doron Shabat, Gerhard Gaedicke, Nikolai Siebert, Carrie S. Dolman, Nicole Huebener and Marina Shamis. Their work appears in journals such as Cancers, Proceedings of the National Academy of Sciences, Cancer Letters, Blood and OncoImmunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.